MFC Manulife delivers 46 percent Q4 2025 EPS beat shares register small gains in todays session Alnylam Pharmaceuticals Inc ALNY Phase 2 Diabetes Drug Progress and SP 500 Contender Status Lift Bullish Outlook BRC BRCC Stock Risk Exposure 450 20260427